Business Context and Reporting Period
The provided filing is EyeGate Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, not Kiora Pharmaceuticals, Inc. EyeGate was a clinical-stage ophthalmic pharmaceutical and medical-device company developing EGP-437, an iontophoretic dexamethasone combination product, and EyeGate Ocular Bandage Gel, a CMHA-S-based ocular-surface product.
The company had no approved commercial products and operated primarily as a research and development business. It reported one operating and geographic segment. At December 31, 2017, EyeGate had 17 full-time employees and 17,257,255 common shares outstanding.
Financial Results and Key Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Collaboration revenue | $0.408 million | $0.669 million | Down $0.262 million |
| Research and development expense | $10.330 million | $8.423 million | Up $1.908 million |
| General and administrative expense | $4.636 million | $5.594 million | Down $0.957 million |
| Total operating expenses | $14.967 million | $14.016 million | Up $0.951 million |
| Loss before tax benefit | $14.560 million | $13.343 million | Higher loss by $1.216 million |
| Income tax benefit | $1.342 million | None | Primarily related to the Tax Cuts and Jobs Act |
| Net loss | $13.218 million | $13.343 million | Improved by $0.126 million |
| Basic and diluted loss per share | $0.93 | $1.51 | Improved |
| Net cash used in operating activities | $6.469 million | $8.413 million | Use decreased by $1.945 million |
| Cash and cash equivalents | $7.806 million | $3.635 million | Up $4.171 million |
Revenue consisted of U.S. government grant revenue and did not reflect cash received from Valeant milestone or progress payments, which were recorded as deferred revenue. The company remained pre-revenue from product sales and had an accumulated deficit of $91.817 million.
Total liabilities were $16.232 million, including $12.314 million of deferred revenue, $1.210 million of contingent consideration and $1.399 million of other non-current liabilities. The company reported stockholders’ deficit of $1.927 million. It had no material debt other than trade payables and capital lease obligations.
Material Changes Versus the Prior Comparable Period
- R&D spending increased 23%, primarily because of the Phase 2b post-cataract trial, EyeGate OBG development and higher personnel costs following the Jade acquisition; this was partly offset by lower activity in the earlier anterior-uveitis Phase 3 program.
- G&A expense declined 17%, mainly because 2016 included professional costs associated with the Jade acquisition.
- Operating cash burn improved, largely because of increased Valeant payments and government funding received during 2017.
- Cash increased to $7.806 million after $10.671 million of financing cash inflows, including approximately $1.8 million from the ATM program and $8.8 million from a June 2017 public offering.
- Common shares outstanding increased from 10.131 million to 17.257 million, and the company issued warrants to purchase 6.667 million shares at a $1.50 exercise price in the June 2017 offering.
- The company entered into a February 2017 Valeant license agreement for post-operative ocular inflammation and pain. It received a $4.0 million upfront payment and reported eligibility for approximately $99.0 million of development and commercial milestones, plus royalties.
- Adoption of the new revenue standard on January 1, 2018 was expected to reduce opening accumulated deficit by approximately $9.5 million and change the timing of revenue recognition.
Guidance, Outlook, Risks and Unusual Items
Development and Regulatory Outlook
- EyeGate expected to continue enrolling its confirmatory Phase 3 anterior-uveitis trial and anticipated top-line data in 2018. Management stated that, if the trial met non-inferiority criteria, the trial and the prior Phase 3 study could support an NDA filing, potentially in the second half of 2018.
- For EyeGate OBG, management planned an IDE amendment and additional IDE submission in the first quarter of 2018, with masked pilot trials for post-PRK defects and punctate epitheliopathies expected in the first half of 2018.
- The Phase 2b post-cataract trial reported after year-end showed higher success rates for EGP-437 than vehicle at all time points, but neither co-primary endpoint achieved statistical significance. Management stated that it was evaluating next steps.
- The FDA requested additional manufacturing-process validation work for EyeGate OBG, particularly because the product requires aseptic processing rather than terminal sterilization.
Liquidity and Going-Concern Risk
- Management stated that available cash and expected first-half 2018 receipts would fund planned operations for approximately seven months. The filing states that substantial additional capital would be required.
- The auditor included an explanatory paragraph regarding substantial doubt about the company’s ability to continue as a going concern. The financial statements contained no adjustments for a potential inability to continue operations.
- The company had no committed external funding source and expected to rely on equity or debt financings, licensing transactions, collaborations and grants. Additional financing could dilute shareholders or require the company to surrender valuable rights.
- NASDAQ notified the company in November 2017 that it was below minimum stockholders’ equity, market-value and profitability requirements. A compliance plan was accepted, with a stated deadline of May 21, 2018 to regain compliance.
Other Risks and Unusual Items
- The company’s lead programs remained subject to clinical-trial failure, regulatory delay, manufacturing-validation requirements, patient-enrollment risk and potential additional safety studies, including a planned six-month corneal endothelial-cell safety trial.
- Commercialization depended on third-party manufacturers, CROs, reimbursement, intellectual-property protection and Valeant’s performance under the license agreements. Valeant could terminate either agreement under specified circumstances, including without cause on 90 days’ notice.
- The company recognized a $1.342 million income tax benefit from a partial release of its valuation allowance following the Tax Cuts and Jobs Act. This was a non-operating accounting benefit and did not indicate operating profitability.
- The company had approximately $45.5 million of federal and $33.3 million of state net operating loss carryforwards, but their utilization could be restricted under tax-law ownership-change rules.
Most Important Facts for Investors to Verify
- Verify the issuer identity: the supplied text is an EyeGate Pharmaceuticals 2017 Form 10-K, whereas the request metadata names Kiora Pharmaceuticals.
- Confirm current liquidity, subsequent financing, cash runway and whether the going-concern uncertainty was resolved after December 31, 2017.
- Review subsequent results for the confirmatory Phase 3 anterior-uveitis trial, the post-cataract program and EyeGate OBG regulatory submissions.
- Assess the impact of the approximately $9.5 million revenue-recognition transition adjustment and subsequent recognition of deferred Valeant payments.
- Review NASDAQ listing compliance and any later reverse split, delisting, financing or capital-structure actions.
- Evaluate dilution from the 17.257 million shares outstanding, 9.456 million warrants and 1.893 million employee stock options reported at year-end.
- Confirm the enforceability, milestone economics and termination provisions of the Valeant license agreements.